MHC compatibility influences the interaction between different types of equine mesenchymal stem/stromal cells and the local immune response.

Overview

• This research investigates how the compatibility of major histocompatibility complex (MHC) between donor and recipient influences the immune response to different types of equine mesenchymal stem/stromal cells (MSCs) when implanted in horses.
• The study evaluates how MHC matching impacts the immune environment and the immunomodulatory behavior of MSCs, thereby informing strategies for effective and safe stem cell-based therapies in veterinary medicine.

Background and Purpose

• Equine MSC Therapy: MSCs are stem/stromal cells with regenerative and immunomodulatory properties being explored for therapeutic use in horses.
• Allogeneic vs. Autologous: Using donor (allogeneic) MSCs instead of the patient’s own cells (autologous) offers practical advantages like immediate availability but can trigger immune responses.
• Immune System Interaction: The degree of immune reaction depends on compatibility between the donor’s and recipient’s major histocompatibility complex (MHC), a critical part of the immune recognition system.
• MHC Expression and Conditions: MSCs can differ in their MHC expression depending on their differentiation or exposure to inflammatory stimuli, affecting their interaction with the immune system.
• Study Goal: To understand how three kinds of MSC conditions—naïve (untreated), chondrogenically differentiated, and pro-inflammatory primed—interact with the local immune response in horses with matched and mismatched MHC backgrounds.

Methods

• MSC Preparation: Equine MSCs were prepared in three conditions: MSC-naïve (basal), MSC-chondro (chondrogenically differentiated), and MSC-primed (pro-inflammatory treated).
• Implantation Procedure: MSCs embedded in alginate scaffolds were implanted subcutaneously into horses grouped based on autologous, MHC-matched, or MHC-mismatched status relative to the MSC donor.
• Sampling and Analysis: Scaffolds were retrieved at different time points for histological analysis and gene expression profiling of immunogenic and immunomodulatory markers.
• Repeated Administration: The implantation process was repeated to evaluate immune responses upon a second exposure to the MSCs.

Key Findings

• MHC Compatibility Mitigates Immune Response: When MSCs were implanted in MHC-matched or autologous horses, the local immune response was lower, indicating better immune tolerance.
• Immunomodulatory Gene Upregulation: In all MSC types under MHC-matched conditions, immunomodulatory genes were elevated, suggesting MSCs actively modulate the immune environment favorably.
• Increased Immunogenicity in MHC-mismatched Cases: MSC administration in MHC-mismatched horses resulted in higher expression of immunogenic genes, indicating stronger immune activation and possible rejection risks.
• MSC Condition Less Impactful than MHC Status: Differences in MSC differentiation or priming state did not meaningfully alter long-term immune outcomes compared to MHC compatibility effects.
• Repeated MSC Administration: Repeated injections showed similar immune response patterns, emphasizing that MHC matching is especially critical when multiple treatments are planned.

Implications and Conclusions

• Clinical Relevance: MHC matching should be prioritized for allogeneic equine MSC therapies to reduce immune rejection and improve treatment success.
• Immune Evasion by MSCs: MSCs can evade immune detection better when MHC is compatible, highlighting the importance of donor-recipient selection in veterinary stem cell applications.
• Therapeutic Strategy: Even though MSCs can be primed or differentiated for specific regenerative purposes, their immunological compatibility with the host has a greater influence on safety and efficacy.
• Future Research: Comprehensive in vivo studies, like this one, are needed to better understand the immunological dynamics of stem cell therapies, advancing the field of veterinary regenerative medicine.